Colorado is currently home to 1810 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394
Recruiting
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric par... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/04/2025
Locations: Advanced Neurosciences Research, LLC /ID# 247592, Fort Collins, Colorado
Conditions: Episodic Migraine
Register for Updates
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
NCT02332668
Recruiting
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared) * Refractory, which means cancer did not respond to previous treatment Pembrolizumab is... Read More
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
07/04/2025
Locations: Call for Information (Investigational Site 0019), Aurora, Colorado
Conditions: Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
Register for Updates
Virtual Reality Treatment for Adults With Chronic Back Pain (VRNT)
NCT07033195
Recruiting
Participants with chronic back pain will complete an online Qualtrics eligibility survey. After signing a consent form, eligible participants enter a two-week baseline period ("Baseline Period") during which they complete two assessments of the Primary and Secondary Outcome Measures and Potential Mediators. After the baseline period, participants are randomized into a treatment group ("Therapy Group") or a control intervention group ("Control Group") with a ratio of 1:1 (treatment:control). Both... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/03/2025
Locations: University of Colorado Boulder, Boulder, Colorado
Conditions: Chronic Pain, Chronic Back Pain, Chronic Lower Back Pain (CLBP)
Register for Updates
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080
Recruiting
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME). In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be ent... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Colorado Springs, CO, Colorado Springs, Colorado
Conditions: Diabetic Macular Edema (DME)
Register for Updates
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
NCT06559189
Recruiting
This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.
Gender:
ALL
Ages:
Between 3 months and 30 years
Trial Updated:
07/03/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
NCT06430541
Recruiting
The goal of this clinical trial is to test whether psilocybin along with therapy in women with early breast cancer and ovarian cancer in remission can improve their fear of recurrence. The main question\[s\] it aims to answer \[is/are\]: Does psilocybin assisted therapy improve fear of cancer recurrence? Does psilocybin assisted therapy improve anxiety, depression, and quality of life? Participants will complete a series of survey measures, participate in preparatory therapy. After prep therap... Read More
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
07/03/2025
Locations: Outpatient CTRC, Aurora, Colorado
Conditions: Breast Cancer, Ovarian Cancer
Register for Updates
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/03/2025
Locations: Clinical Site, Colorado Springs, Colorado
Conditions: Bipolar Depression
Register for Updates
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169
Recruiting
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic steatohepatitis \[NASH\]).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/03/2025
Locations: 89bio Clinical Study Site, Littleton, Colorado
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Register for Updates
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037
Recruiting
This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
Register for Updates
Advancing Rehabilitation Paradigms for Older Adults in Skilled Nursing Facilities
NCT05492240
Recruiting
This cluster randomized clinical trial seeks to provide large-scale, foundational evidence that high-intensity rehabilitation is effective and can be systematically implemented to improve functional outcomes for patients admitted to skilled nursing facilities following hospitalization. Additionally, this study will generate a descriptive overview of factors that predict implementation success while informing effective implementation strategies for future skilled nursing facilities innovation.
Gender:
ALL
Ages:
Between 50 years and 120 years
Trial Updated:
07/03/2025
Locations: University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado
Conditions: Aging, Functional Recovery, Skilled Nursing Facility, Medically Complex, Deconditioning
Register for Updates
ALTERRA Post-Approval Study
NCT05378386
Recruiting
This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting
Gender:
ALL
Ages:
All
Trial Updated:
07/03/2025
Locations: Colorado Children's Hospital, Aurora, Colorado
Conditions: Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation, RVOT Anomaly
Register for Updates
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT06919666
Recruiting
Fixed dose NT219 weekly plus pembrolizumab every 3 weeks or cetuximab weekly to be continued until progression, unacceptable toxicity, or investigator or participant decision.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Universtiy of Colorado Hospital, Aurora, Colorado
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates